×
About 165 results

ALLMedicine™ Prostate Cancer Staging Center

Research & Reviews  55 results

Comparison of Multiparametric Prostate MRI and Ga-68 PSMA PET Imaging in Prostate Cancer Staging
https://clinicaltrials.gov/ct2/show/NCT05427864

Jun 22nd, 2022 - In this study, it is aimed to compare the lesion location, lesion size, local and distant metastases detection rates of Ga68 PSMA PET and Multiparametric Prostate MR imaging tests used in staging in patients diagnosed with prostate cancer. The pat...

Calibrated Regression Models Based on the Risk of Clinical Nodal Metastasis Should be U...
https://doi.org/10.1016/j.clgc.2022.05.003
Clinical Genitourinary Cancer; Hayes M, Yu Y et. al.

Jun 2nd, 2022 - Radionuclide imaging will change the role of computed tomography and magnetic resonance imaging (CT/MRI) for prostate cancer (CaP) staging. Current guidelines recommend abdominopelvic imaging for new cases of CaP categorized as unfavorable interme...

The role of prostate-specific membrane antigen PET/computed tomography in the managemen...
https://doi.org/10.1097/MOU.0000000000000982
Current Opinion in Urology; Mei R, Farolfi A et. al.

May 14th, 2022 - Thanks to the development of novel PSMA-based peptides, molecular imaging, such as PET/CT paired with theranostic-based approaches have recently been proposed for treatment of prostate cancer. Patient selection, however, remains challenging becaus...

ReIMAGINE Prostate Cancer Risk
https://clinicaltrials.gov/ct2/show/NCT04060589

Apr 11th, 2022 - ReIMAGINE Prostate Cancer Risk is a multi-centre, prospective, observational, longitudinal cohort study of men referred to secondary care with a suspicion of prostate cancer or men who are undergoing further tests for prostate cancer staging asses...

Accuracy of 68Ga-PSMA PET/CT for lymph node and bone primary staging in prostate cancer.
https://doi.org/10.1016/j.urolonc.2021.11.007
Urologic Oncology; Moreira LF, Mussi TC et. al.

Dec 17th, 2021 - The aim of this study is to assess the accuracy of the 68Ga-PSMA PET/CT for lymph nodes and bones in the primary stage of prostate cancer. A total of 126 patients who were submitted to 68Ga-PSMA PET/CT from January 2016 to February 2019 for prosta...

see more →

Clinicaltrials.gov  5 results

Comparison of Multiparametric Prostate MRI and Ga-68 PSMA PET Imaging in Prostate Cancer Staging
https://clinicaltrials.gov/ct2/show/NCT05427864

Jun 22nd, 2022 - In this study, it is aimed to compare the lesion location, lesion size, local and distant metastases detection rates of Ga68 PSMA PET and Multiparametric Prostate MR imaging tests used in staging in patients diagnosed with prostate cancer. The pat...

ReIMAGINE Prostate Cancer Risk
https://clinicaltrials.gov/ct2/show/NCT04060589

Apr 11th, 2022 - ReIMAGINE Prostate Cancer Risk is a multi-centre, prospective, observational, longitudinal cohort study of men referred to secondary care with a suspicion of prostate cancer or men who are undergoing further tests for prostate cancer staging asses...

Robot-Assisted MRI-Guided Prostate Biopsy
https://clinicaltrials.gov/ct2/show/NCT02080052

Jan 14th, 2019 - While prostate cancer is the most common non-dermatologic malignancy among men in the US, it is frequently indolent and may not require radical therapy, i.e. radical prostatectomy or external beam radiotherapy. There has been increased interest in...

The Effect of ADT on PSMA-PET.
https://clinicaltrials.gov/ct2/show/NCT03313726

Oct 18th, 2017 - Positron emission tomography has been commonly and successfully used, in combination with CT and MRI devices, in the staging of intermediate or high risk prostate cancer. Proper staging is essential to guide the treatment options, which usually ar...

[18F] Fluorocholine FCH Positron Emission Tomography (PET)/Computed Tomography (CT) for Detection of Prostate Cancer Lymph Nodes Metastases
https://clinicaltrials.gov/ct2/show/NCT00670527

Oct 8th, 2012 - The purpose of this prospective trail is to improve the staging of patients with prostate cancer. The investigators focus on the group of patients with a newly diagnosed prostate cancer, and specifically the ones who have an intermediate and high ...

see more →

News  5 results

New Prostate Cancer Staging System May Improve Pretreatment Prognostication
https://www.staging.medscape.com/viewarticle/940086

Nov 2nd, 2020 - NEW YORK (Reuters Health) - A pretreatment, predictive staging system for nonmetastatic prostate cancer, based on data analysis rather than expert consensus, promises to improve on existing risk-stratification systems, according to an internationa...

New Prostate Cancer Staging System May Improve Pretreatment Prognostication
https://www.medscape.com/viewarticle/940086

Nov 2nd, 2020 - NEW YORK (Reuters Health) - A pretreatment, predictive staging system for nonmetastatic prostate cancer, based on data analysis rather than expert consensus, promises to improve on existing risk-stratification systems, according to an internationa...

PSMA PET/CT may be new ‘gold standard’ for prostate cancer staging
https://www.mdedge.com/hematology-oncology/article/225768/genitourinary-cancer/psma-pet/ct-may-be-new-gold-standard
Sara Freeman

Jul 21st, 2020 - Prostate-specific membrane antigen (PSMA) PET/CT was 27% more accurate than conventional imaging for detecting metastases and staging men prior to curative-intent therapy for high-risk prostate cancer in the phase 3 ProPSMA study. The accuracy was.

SEER Data Errors: NCI Looks To Avoid Repeats
https://www.medpagetoday.com/hematologyoncology/prostatecancer/55401

Dec 23rd, 2015 - In July, it was learned that officials at the National Cancer Institute (NCI) had decided to withhold prostate-specific antigen data to its Surveillance Epidemiology and End Results (SEER) database from the 2014 update because of problems in that ...

The Use of Imaging in Prostate Cancer Staging—A Utilization Review
https://www.mdedge.com/fedprac/avaho/article/102763/oncology/use-imaging-prostate-cancer-staging-utilization-review

Sep 18th, 2015 - Purpose: To evaluate how well the Providence VA Medical Center (PVAMC) follows established National Comprehensive Cancer Network (NCCN) guidelines regarding imaging criteria for the staging of newly diagnosed patients with limited stage prostate c.

see more →

Patient Education  1 results see all →